Consun Pharmaceutical Group (CPHG.F) Stock Overview
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
CPHG.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Consun Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.65 |
| 52 Week High | HK$2.00 |
| 52 Week Low | HK$1.12 |
| Beta | 0.56 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 58.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPHG.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.01% | -0.3% |
| 1Y | n/a | 30.2% | 15.4% |
Return vs Industry: Insufficient data to determine how CPHG.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CPHG.F performed against the US Market.
Price Volatility
| CPHG.F volatility | |
|---|---|
| CPHG.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CPHG.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CPHG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,073 | Meng An | www.chinaconsun.com |
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products.
Consun Pharmaceutical Group Limited Fundamentals Summary
| CPHG.F fundamental statistics | |
|---|---|
| Market cap | US$1.86b |
| Earnings (TTM) | US$144.79m |
| Revenue (TTM) | US$468.85m |
Is CPHG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPHG.F income statement (TTM) | |
|---|---|
| Revenue | CN¥3.27b |
| Cost of Revenue | CN¥764.01m |
| Gross Profit | CN¥2.50b |
| Other Expenses | CN¥1.49b |
| Earnings | CN¥1.01b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.20 |
| Gross Margin | 76.62% |
| Net Profit Margin | 30.88% |
| Debt/Equity Ratio | 5.1% |
How did CPHG.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/18 11:29 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Consun Pharmaceutical Group Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fangqi Dai | China Merchants Securities (HK) Co., Ltd |
| Zhuhong Chen | China Merchants Securities (HK) Co., Ltd |
| null null | CMB International Securities Limited |